好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Toward Objective Monitoring of Motor Fluctuations in Parkinson’s Disease: TMS-EEG Biomarkers
Movement Disorders
P1 - Poster Session 1 (8:00 AM-9:00 AM)
16-002

Searching for a neurophysiological marker of ON/OFF state in PD

 

Motor fluctuations (MF) in Parkinson’s disease (PD) are episodic changes in motor performance due to variable responses to levodopa therapy, marked by "on" and "off" periods. Current assessments rely on subjective patient reports and clinical observation, which may miss subtle changes. Neurophysiological markers obtained from transcranial magnetic stimulation combined with electroencephalography (TMS-EEG) hold promise as objective indicators of cortical excitability related to motor function.

In a single visit, consecutive PD patients who are regularly treated with levodopa and experience significant MF, underwent a clinical assessment using the Movement Disorder Society-Unified PD Rating Scale (MDS-UPDRS), with part III rated in both "on" and "off" conditions. They also completed a TMS-EEG-based test called Delphi-MD in each state. 

Eighteen patients (mean age 59.4±19.1 years; 72.2% males; disease duration 10.8±8.8 years; LEDD 906.8±349.1 mg) participated. A repeated measures t-test showed that the TMS-EEG GMFP of the right primary motor cortex (M1R) significantly distinguished "on" vs. "off" states (p<0.000536). Regression analysis, controlled for LEDD, revealed that ?GMFP N100 of primary visual cortex (V1R) variability explained about 49.9% of the variance in motor improvement (ΔMDS-UPDRS-III, F(2,13)=6.46, p=0.011, adjusted R²=0.42). Larger N100 amplitude increases in V1R (visual cortex) strongly predicted greater motor improvement (β=–0.79, p=0.003). LEDD showed a non-significant trend.

TMS-EEG measures from motor and occipital regions may serve as objective biomarkers of dopaminergic response in fluctuating PD. The motor cortex distinctly differentiates "on" and "off" states, while the visual cortex might provide real-time, continuous feedback on levodopa effects. These neurophysiological markers could reduce reliance on subjective assessments and improve monitoring and personalized treatment.

Authors/Disclosures
Hilla Fogel, PhD
PRESENTER
Dr. Fogel has received personal compensation for serving as an employee of QuantalX Neuroscience. Dr. Fogel has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for QuantalX Neuroscience. Dr. Fogel has received intellectual property interests from a discovery or technology relating to health care.
Tsviya Fay-Karmon, MD No disclosure on file
Tal Davidy, MD (Tel hashomer) Dr. Davidy has nothing to disclose.
Alexandra Suminski (Sheba Medical Center) No disclosure on file
Hassin a. Adi Miss Adi has nothing to disclose.
Tal Bar-dor, BSc Ms. Bar-dor has nothing to disclose.
Noa Zifman, MSc Mrs. Zifman has received personal compensation for serving as an employee of QuantalX Neuroscience Ltd.. Mrs. Zifman has received intellectual property interests from a discovery or technology relating to health care.
Sharon Hassin-Baer, MD (Chaim Sheba Medical Center) Dr. Hassin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ABBVIE. Dr. Hassin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MEDISON. Dr. Hassin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TEVA. Dr. Hassin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ABBVIE. Dr. Hassin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ABBVIE. Dr. Hassin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA.